Colon cancer therapy: Recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 1204-1216

  Prados, J ^a   Melguizo, C ^a   Ortiz, R ^b   Perazzoli, G ^a   Cabeza, L ^a   Alvarez P J ^a   Rodriguez Serrano, F ^a   Aranega, A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

5 fluorouracil; Chitosan; Colon cancer; Cytotoxic drugs; Drug resistance; Nanoparticles; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; C REACTIVE PROTEIN; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CARBOXYMETHYLDEXTRAN; CELECOXIB; CETUXIMAB; CHITOSAN; CHITOSAN NANOPARTICLE; DOXORUBICIN; FLAVONOID; FLUOROURACIL; FOLINIC ACID; HYALURONIC ACID; HYDROXYAPATITE; INTERLEUKIN 12; INTERLEUKIN 6; IRINOTECAN; LACTOFERRIN; LECTIN; MAGNETIC NANOPARTICLE; NANOPARTICLE; OXALIPLATIN; POLYCAPROLACTONE; POLYGLACTIN; QUERCETIN; SOLID LIPID NANOPARTICLE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; CLINICAL TRIAL (TOPIC); COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HUMAN; IMMUNOGENICITY; MISMATCH REPAIR; MULTIDRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE IMAGING;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MAGNETITE NANOPARTICLES; NANOPARTICLES;

EID: 84888227025     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990325     Document Type: Article

References (148)

1. Ferlay, J.; Bray, F.; Pisani, P.; Parkin, D.M. Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press, 2004.
2. Labianca, R.; Beretta, G.D.; Kildani, B.; Milesi, L.; Merlin, F.; Mosconi, S.; Pessi, M.A.; Prochilo, T.; Quadri, A.; Gatta, G.; de Braud, F.; Wils, J. Colon cancer. Crit. Rev. Oncol. Hematol., 2010, 74(2),106-133.
3. Van Cutsem, E.; Kohne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D'Haens, G.; Pinter, T.; Lim, R.; Bodoky, G.; Roh, J.K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 2009, 360(14), 1408-1417.
4. Berrino, F; De A.R.; Sant, M.; Rosso, S.; Bielska-Lasota, M.; Coebergh, J.W.; Santaquilani, M.; EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol., 2007, 8(9), 773-783.
5. Rahman, Z.; Kohli, K.; Khar, R.K.; Ali, M.; Charoo, N.A.; Shamsher, A.A. Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS PharmSciTech., 2006, 7(2), E47.
6. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of cancer drugs. Annu Rev. Med., 2011, 63, 185-198.
7. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4(2), 145-160.
8. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol., 2005, 23(31), 7794-7803.
9. Banerjee, D.; Sengupta, S. Nanoparticles in cancer chemotherapy. Prog. Mol. Biol. Transl. Sci., 2011, 104, 489-507.
10. Blanco, E.; Hsiao, A.; Mann, A.P.; Landry, M.G.; Meric-Bernstam, F.; Ferrari, M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci., 2011, 102(7), 1247-1252.
11. Lai, P.S.; Shieh, M.J.; Pai, C.L.; Wang, C.Y.; Young, T.H. A pH-sensitive EVAL membrane by blending with PAA. J. Memb. Sci., 2006, 275, 89-96.
12. Sastre, R.L.; Olmo, R.; Teijon, C.; Muniz, E.; Teijon, J.M.; Blanco, M.D. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers. Int. J. Pharm., 2007, 338(1-2), 180-190.
13. Johnston, P.G.; Lenz, H.J.; Leichman, C.G.; Danenberg, K.D.; Allegra, C.J.; Danenberg, P.V.; Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 1995, 55(7), 1407-1412.
14. Peters, G.J.; Backus, H.H.; Freemantle, S.; van Triest, B.; Codacci- Pisanelli, G.; van der Wilt, C.L.; Smid, K.; Lunec, J.; Calvert, A.H.; Marsh, S.; McLeod, H.L.; Bloemena, E.; Meijer, S.; Jansen, G.; van Groeningen, C.J.; Pinedo, H.M. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta, 2002, 1587(2-3), 194-205.
15. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; Tabah-Fisch, I.; de Gramont, A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med., 2004, 350(23), 2343-2351.
16. Mayer, R.J. Targeted therapy for advanced colorectal cancer-more is not always better. N. Engl. J. Med., 2009, 360(6), 623-625.
17. Chen, Y.; Tang, Y.; Guo, C.; Wang, J.; Boral, D.; Nie, D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol., 2012, 83(8), 1112-1126.
18. Casale, F.; Canaparo, R.; Serpe, L.; Muntoni, E.; Pepa, C.D.; Costa, M.; Mairone, L.; Zara, G.P.; Fornari, G.; Eandi, M. Plasma concentration of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol. Res., 2004, 50(2), 173-179.
19. Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med., 2005, 352(5), 476-487.
20. Wolpin, B.M.; Mayer, R.J. Systemic treatment of colorectal cancer. Gastroenterology, 2008, 134(5), 1296-1310.
21. Soreide, K.; Berg, M.; Skudal, B.S.; Nedreboe, B.S. Advances in the understanding and treatment of colorectal cancer. Discov. Med., 2011, 12(66), 393-404.
22. Kucuk, C.; Ozkan, M.; Akgun, H.; Muhtaroglu, S.; Sozuer, E. The effect of granulocyte macrophage-colony stimulating factor on bacterial translocation after administration of 5-fluorouracil in rats. J. Surg. Res., 2005, 128(1), 15-20.
23. Yin, Y.; Chen, D.; Qiao, M.; Lu, Z.; Hu, H. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release., 2006, 116(3), 337-345.
24. Glavas Dodov, M.; Calis, S.; Crcarevska, M.S.; Geskovski, N.; Petrovska, V.; Goracinova, K. Wheat germ agglutinin-conjugated chitosan-Ca-alginate microparticles for local colon delivery of 5- FU: development and in vitro characterization. Int. J. Pharm., 2009, 381(2), 166-175.
25. Yadav, S.; van Vlerken, L.E.; Little, S.R.; Amiji, M.M. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer. Cancer Chemother. Pharmacol., 2009, 63(4), 711-722.
26. Fodale, V.; Pierobon, M.; Liotta, L.; Petricoin, E. Mechanism of cell adaptation when and how do cancer cells develop chemoresistance? Cancer J., 2011, 17(2), 95-98.
27. Potocnik, U.; Ravnik-Glavac, M.; Golouh, R.; Glavac, D.J. Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J. Med. Genet., 2002, 39(5), 340-346.
28. Schumacher, U.; Nehmann, N.; Adam, E.; Mukthar, D.; Slotki, I.N.; Horny, H.P.; Flens, M.J.; Schlegelberger, B.; Steinemann, D. MDR-1-overexpression in HT 29 colon cancer cells grown in SCID mice. Acta Histochem., 2012, 114(6), 594-602.
29. Levchenko, A.; Mehta, B.M.; Niu, X.; Kang, G.; Villafania, L.; Way, D.; Polycarpe, D.; Sadelain, M.; Larson, S.M. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(6), 1933-1938.
30. Bebawy, M.; Combes, V.; Lee, E.; Jaiswal, R.; Gong, J.; Bonhoure, A.; Grau, G.E. Membrane microparticles mediate transfer of p- glycoprotein to drug sensitive cancer cells. Leukemia, 2009, 23(9), 1643-1649.
31. Koziara, J.M.; Whisman, T.R.; Tseng, M.T.; Mumper, R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Realease., 2006, 112(3), 312-319.
32. Riganti, C.; Voena, C.; Kopecka, J.; Corsetto, P.A.; Montorfano, G.; Enrico, E.; Costamagna, C.; Rizzo, A.M.; Ghigo, D.; Bosia, A. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting p-glycoprotein in human cancer cells. Mol. Pharm., 2011, 8(3), 683-700.
33. Mader, R.M.; Müller, M.; Steger, G.G. Resistance to 5- Fluorouracil. Gen. Pharmac., 1998, 31(5), 661-666.
34. Johnston, P.G.; Fisher, E.R.; Rockette, H.E.; Fisher, B.; Wolmark, N.; Drake, J.C.; Chagner, B.A.; Allegra, C.J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 1994, 12(12), 2640-2647.
35. Popat, S.; Matakidou, A.; Oulston, R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol., 2004, 22(3), 529-536.
36. Schmitz, J.C.; Chu, E. Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors. Silence, 2011, 2(1), 1-10.
37. Meyers, M.; Wagner, M.W.; Hwang, H.S.; Kinsella, T.J.; Boothman, D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res., 2001, 61(13), 5193-5201.
38. Li, P.; Wang, Y.; Zeng, F.; Chen, L.; Peng, Z.; Kong, L.X. Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydr. Res., 2011, 346(6), 801-806.
39. Harish Prashanth, K.V.; Tharanathan, R.N. Chitin/chitosan: modifications and their unlimited application potential-an overview. Trends Food Sci. Technol., 2007, 18(3), 117-131.
40. Sajomsang, W.; Gonil, P.; Tantayanon, S. Antibacterial activity of quaternary ammonium chitosan containing mono or disaccharide moieties: preparation and characterization. Int. J. Biol. Macromol., 2009, 44(5), 419-427.
41. Wang, T.; Xu, Q.; Wu, Y.; Zeng, A.; Li, M.; Gao, H. Quaternized chitosan (QCS)/poly (aspartic acid) nanoparticles as a protein drug- delivery system. Carbohydr. Res., 2009, 344(7), 908-914.
42. Li, P.; Wang, Y.; Peng, Z.; She, F.; Kong, L. Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohydr. Polymers, 2011, 85(3), 698-704.
43. Peterson, R.M.; Yu, Q.; Stamenkovic, I.; Toole, B.P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol., 2000, 156(6), 2159-2167.
44. Zeng, C.; Toole, B.P.; Kinney, S.D.; Kuo, J.W.; Stamenkovic, I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer, 1998, 77(3), 396-401.
45. Lokeshwar, V.B.; Obek, C.; Pham, H.T.; Wei, D.; Young, M.J.; Duncan, R.C.; Soloway, M.S.; Block, N.L. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J. Urol., 2000, 163(1), 348-356.
46. Knudson, W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am. J. Pathol., 1996, 148(6), 1721-1726.
47. Jain, A., Jain, S.K. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur. J. Pharm. Sci., 2008, 35(5), 404-416.
48. Culy, C.R.; Clemett, D.; Wiseman, L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs, 2000, 60(4), 895-924.
49. Jain, A.; Jain, S.K.; Ganesh, N.; Barve, J.; Beg, A.M. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine, 2010, 6(1), 179-190.
50. Urbanska, A.M.; Karagiannis, E.D. Guajardo, G.; Langer, R.S.; Anderson, D.G. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer. Biomaterials, 2012, 33(18), 4752-4761.
51. Hosseinzadeh, H.; Atyabi, F.; Dinarvand, R.; Ostad, S.N. Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int. J. Nanomed., 2012, 7, 1851-1863.
52. Chuah, L.H.; Billa, N.; Roberts, C.J.; Burley, J.C.; Manickam, S. Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. Pharm. Dev. Technol., 2011, 1-9.
53. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2); 153-159.
54. Peppas, N.A.; Huang, Y. Nanoscale technology of mucoadhesive interactions. Adv. Drug. Deliv. Rev., 2004, 56(11), 1675-1687.
55. Mateus, A.Y.; Barrias, C.C.; Ribeiro, C.; Ferraz, M.P.; Monteiro, F.J. Comparative study of nanohydroxyapatite microspheres for medical applications. J. Biomed. Mater. Res. A., 2008, 86(2), 483-493.
56. Liu, Z.S.; Tang, S.L.; Ai, Z.L. Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells. World. J. Gastroenterol., 2003, 9(9), 1968-1971.
57. Li, J.; Yin, Y.; Yao, F.; Zhang, L.; Yao, K. Effect of nano-andmicro-hydroxyapatite/chitosan-gelatin network film on human gastric cancer cells. Mater. Lett., 2008, 62(17-18), 3220-3223.
58. Hsiao, P.W.; Chang, C.C.; Liu, H.F.; Tsai, C.M.; Chiu, T.H. Chao, J.I. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol. Appl. Pharmacol., 2007, 222(1), 97-104.
59. Bijman, M.N.; Hermelink, C.A.; van Berkel, M.P.; Laan, A.C.; Janmaat, M.L.; Peters, G.J.; Boven, E. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem. Pharmacol., 2008, 75(2), 427-437.
60. Mohammed, S.I.; Dhawan, D.; Abraham, S.; Snyder, P.W.; Waters, D.J.; Craig, B.A.; Lu, M.; Wu, L.; Zheng, R.; Stewart, J.; Knapp, D.W. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol. Cancer. Ther., 2006, 5(2), 329-336.
61. Auman, J.T.; Church, R.; Lee, S.Y.; Watson, M.A.; Fleshman, J.W.; McLeod, H.L. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur. J. Cancer, 2008, 44(12), 1754-1760.
62. Paulson, S.K.; Zhang, J.Y.; Breau, A.P.; Hribar, J.D.; Liu, N.W.; Jessen, S.M.; Lawal, Y.M.; Cogburn, J.N.; Gresk, C.J.; Markos, C.S.; Maziasz, T.J.; Schoenhard, G.L.; Burton, E.G. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug. Metab. Dispos. 2000, 28(5), 514-521.
63. Venkatesan, P.; Puvvada, N.; Dash, R.; Prashanth Kumar, B.N.; Sarkar, D.; Azab, B.; Pathak, A.; Kundu, S.C.; Fisher, P.B.; Mandal, M. The potential of celecoxib-loaded hydroxyapatite- chitosan nanocomposite for the treatment of colon cancer. Biomaterials, 2011, 32(15), 3794-3806.
64. Ravi Kumar, M.N. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci., 2000, 3(2), 234-258.
65. Yassin, A.E.; Anwer, M.K.; Mowafy, H.A.; El-Bagory, I.M.; Bayomi, M.A.; Alsarra, I.A. Optimization of 5-flurouracil solid- lipid nanoparticles: a preliminary study to treat colon cancer. Int. J. Med. Sci., 2010, 7(6), 398-408.
66. Santini, V.; Gozzini, A.; Scappini, B.; Grossi, A.; Rossi Ferrini, P. Searching for the magic bullet against cancer: the butyrate saga. Leuk. Lymphoma, 2001, 42(3), 275-289.
67. McIntyre, A.; Gibson, P.R.; Young, G.P. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut, 1993, 34(3), 386-391.
68. Barnard, J.A.; Warwick, G. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ., 1993, 4(6), 495-501.
69. Brioschi, A.; Zara, G.P.; Calderoni, S.; Gasco, M.R.; Mauro, A. Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules, 2008, 13(2), 230-254.
70. Minelli, R.; Serpe, L.; Pettazzoni, P.; Minero, V.; Barrera, G.; Gigliotti, C.L.; Mesturini, R.; Rosa, A.C.; Gasco, P.; Vivienza, N.; Muntoni, E.; Fantozzi, R.; Dianzani, U.; Zara, G.P.; Dianzani, C. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br. J. Pharmacol., 2012, 166(2), 587-601.
71. Hollman, P.C.; Katan, M.B. Dietary flavonoids: intake, health effects and bioavailability. Food Chem. Toxicol., 1999, 37(9-10), 937-942.
72. Vijayababu, M.R.; Kanagaraj, P.; Arunkumar, A.; Ilangovan, R.; Aruldhas, M.M.; Arunakaran, J. Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J. Cancer Res. Clin. Oncol., 2005, 131(11), 765-771.
73. Khaled, K.A.; El-Sayed, Y.M.; Al-Hadiya, B.M. Disposition of the flavonoid quercetin in rats after single intravenous and oral doses. Drug Dev. Ind. Pharm., 2003, 29(4), 397-403.
74. Li, H.; Zhao, X.; Ma, Y.; Zhai, G.; Li, L.; Lou, H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release, 2009, 133(3), 238-244.
75. Serpe, L.; Catalano, M.G.; Cavalli, R.; Ugazio, E.; Bosco, O.; Canaparo, R.; Muntoni, E.; Frairia, R.; Gasco, M.R.; Eandi, M.; Zara, G.P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm., 2004, 58(3), 673-680.
76. Su, C.H.; Sheu, H.S.; Lin, C.Y.; Huang, C.C.; Lo, Y.W.; Pu, Y.C.; Weng, J.C.; Shieh, D.B.; Chen, J.H.; Yeh, C.S. Nanoshell magnetic resonance imaging contrast agents. J. Am. Chem. Soc., 2007, 129(7), 2139-2146.
77. Yoon, T.J.; Kim, J.S.; Kim, B.G.; Yu, K.N.; Cho, M.H.; Lee, J.K. Multifunctional nanoparticles possessing a magnetic motor effect for drug or gene delivery. Angew. Chem. Int. Ed. Engl., 2005, 44(7), 1068-1071.
78. Yoon, T.J.; Yu, K.N.; Kim, E.; Kim, J.S.; Kim, B.G.; Yun, S.H.; Sohn, B.H.; Cho, M.H.; Lee, J.K.; Park, S.B. Specific targeting, cell sorting, and bioimaging with smart magnetic silica core-shell nanomaterials. Small, 2006, 2(2), 209-215.
79. Zeng, F.; Lee, H.; Allen, C. Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug. Chem., 2006, 17(2), 399-409.
80. Sorkin, A.; Goh, L.K. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell. Res., 2009, 315(4), 683-696.
81. Bhirde, A.A.; Patel, V.; Gavard, J.; Zhang, G.; Sousa, A.A.; Masedunskas, A.; Leapman, R.D.; Weigert, R.; Gutkind, J.S.; Rusling, J.F. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano, 2009, 3(2), 307-316.
82. Creixell, M.; Herrera, A.P.; Ayala, V.; Latorre-Esteves, M.; Pérez- Torres, M.; Torres-Lugo, M.; Rinaldi, C. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J. Magn. Magn. Mater., 2010, 322(15), 2244-2250.
83. Messa, C.; Russo, F.; Caruso, M.G.; Di Leo, A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol., 1998, 37(3), 285-289.
84. Porebska, I.; Harlozinska, A.; Bojarowski, T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol., 2000, 21(2), 105-115.
85. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1995, 1(11), 1311-1318.
86. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med., 2008, 358(11), 1160-1174.
87. Cho, Y.S.; Yoon, T.J.; Jang, E.S.; Soo Hong, K.; Young Lee, S.; Ran Kim, O.; Park, C.; Kim, Y. J.; Yi, G.C.; Chang, K. Cetuximab- conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett., 2010, 299(1), 63-71.
88. Hsieh, W.J.; Liang, C.J.; Chieh, J.J.; Wang, S.H.; Lai, I.R.; Chen, J.H.; Chang, F.H.; Tseng, W.K.; Yang, S.Y.; Wu, C.C.; Chen, Y.L. In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int. J. Nanomedicine, 2012, 7, 2833-2842.
89. Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev., 2001, 47(1), 113-131.
90. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2003, 2(3), 214-221.
91. Lyon, J.L.; Fleming, D.A.; Stone, M.B.; Schiffer, P; Williams, M.E. Synthesis of Fe Oxide Core/Au shell nanoparticles by iterative hydroxylamine seeding. Nano Lett., 2004, 4(4), 719-723.
92. Kumagai, M.; Sarma, T.K.; Cabral, H.; Kaida, S.; Sekino, M.; Herlambang, N.; Osada, K.; Kano, M.R.; Nishiyama, N.; Kataoka, K. Enhanced in vivo magnetic resonance imaging of tumors by PEGylated iron-oxide-gold core-shell nanoparticles with prolonged blood circulation properties. Macromol. Rapid Commun., 2010, 31(17), 1521-1528.
93. Cho, S.J.; Idrobo, J.C.; Olamit, J.; Liu, K.; Browning, N.D.; Kauzlarich, S.M. Growth mechanisms and oxidation resistance of gold-coated iron nanoparticles. Chem. Mater., 2005, 17(12), 3181-3186.
94. Wu, Y.N.; Chen, D.H.; Shi, X.Y.; Lian, C.C.; Wang, T.Y.; Yeh, C.S.; Ratinac, K.R.; Thordarson, P.; Braet, F.; Shieh, D.B. Cancer- cell-specific cytotoxicity of non-oxidized iron elements in iron core-gold shell NPs. Nanomedicine, 2011, 7(4), 420-427.
95. Zhang, J.; Chen, X.G.; Li, Y.Y.; Liu, C.S. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomed. Nanotechnol., 2007, 3(4), 258-265.
96. Ebrahimnejad, P.; Dinarvand, R.; Sajadi, A.; Jaafari, M.R.; Nomani, A.R.; Azizi, E.; Rad-Malekshahi, M.; Atyabi, F. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine, 2010, 6(3), 478-485.
97. Wang, J.; Peng, C.A. Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2011, 2011, 3249-3252.
98. Jeong Y.I.; Cheon, J.B.; Kim, S.H.; Nah, J.W.; Lee, Y.M.; Sung, Y.K.; Akaike, T.; Cho, C.S. Clonazepam release from core-shell type nanoparticles in vitro. J. Control Release, 1998, 51(2-3), 169-178.
99. Jeong, Y.I.; Kang, M.K.; Sun, H.S.; Kang, S.S.; Kim, H.W.; Moon, K.S.; Lee, K.J.; Kim, S.H.; Jung, S. All-trans-retinoic acid release from core-shell type nanoparticles of poly(epsilon- caprolactone)/poly(ethylene glycol) diblock copolymer. Int. J. Pharm., 2004, 273(1-2), 95-107.
100. Arimura, H.; Ohya, Y.; Ouchi, T. Formation of core-shell type biodegradable polymeric micelles from amphiphilic poly(aspartic acid)-block-polylactide diblock copolymer. Biomacromolecules, 2005, 6(2), 720-725.
101. Jeong, Y.I.; Na, H.S.; Cho, K.O.; Lee, H.C.; Nah, J.W.; Cho, C.S. Antitumor activity of adriamycin-incorporated polymeric micelles of poly(gamma-benzyl L-glutamate)/poly(ethylene oxide). Int. J. Pharm., 2009, 365(1-2), 150-156.
102. Diasio, R.B.; Lu, Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol., 1994, 12(11), 2239-2242.
103. Li, S.; Wang, A.; Jiang, W.; Guan, Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer, 2008, 8, 103-112.
104. Langer, R.; Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature, 1976, 263(5580), 797-800.
105. Shive, M.S.; Anderson, J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug. Deliv. Rev., 1997, 28(1), 5-24.
106. Ling, Y.; Yang, Y.; Lu, N.; You, Q.D.; Wang, S.; Gao, Y.; Chen, Y.; Guo, Q.L. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Commun., 2007, 361(1), 79-84.
107. Zhuo, W.; Luo, C.; Wang, X.; Song, X.; Fu, Y.; Luo, Y. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J. Pathol., 2010, 222(3), 249-260.
108. Hu, S.; Zhang, Y. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int. J. Nanomedicine, 2010, 5, 1039-1048.
109. Chen, W.; Hu, S. Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers. Int. J. Nanomedicine., 2011, 6, 1535-1541.
110. Araki, T.; Kono, Y.; Ogawara, K.; Watanabe, T.; Ono, T.; Kimura, T.; Higaki, K. Formulation and evaluation of Paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic Acid block copolymer. Biol. Pharm. Bull., 2012, 35(8), 1306-1313.
111. Chien, M.H.; Ku, C.C.; Johansson, G.; Chen, M.W.; Hsiao, M.; Su, J.L.; Inoue, H.; Hua, K.T.; Wei, L.H.; Kuo, M.L. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis, 2009, 30(12), 2005-2013.
112. Toomey, D.P.; Murphy, J.F.; Conlon, K.C. COX-2, VEGF and tumour angiogenesis. Surgeon, 2009, 7(3), 174-180.
113. Mondalek, F.G.; Ponnurangam, S.; Govind, J.; Houchen, C.; Anant, S.; Pantazis, P.; Ramanujam, R.P. Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP. J. Nanobiotechnology, 2010, 8, 17-26.
114. De Haan, L.H.; Pot, G.K.; Aarts, J.M.; Rietjens, I.M.; Alink, G.M. In vivo relevance of two critical levels for NAD(P)H:quinone oxidoreductase (NQO1)-mediated cellular protection against electrophile toxicity found in vitro. Toxicol. In Vitro, 2006, 20(5), 594-600.
115. Cabello, C.M.; Bair, W.B.; Bause, A.S.; Wondrak, G.T. Antimelanoma activity of the redox dye DCPIP (2,6- dichlorophenolindophenol) is antagonized by NQO1. Biochem. Pharmacol., 2009, 78(4), 344-354.
116. Cabello, C.M.; Lamore, S.D.; Bair, W.B.; Davis, A.L.; Azimian, S.M.; Wondrak, G.T. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic. Res., 2011, 45(3), 276-292.
117. Mo, Y.; Lim, L. Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J. Control. Release, 2005, 108(2-3), 244-262.
118. Caldero, J.; Campo, E.; Ascaso, C.; Ramos, J.; Panades, M.J.; Rene, J.M. Regional distribution of glycoconjugates in normal, transitional and neoplastic human colonic mucosa. A histochemical study using lectins. Virchows Arch. A. Pathol. Anat. Histopathol., 1989, 415(4), 347-356.
119. Heinrich, E.L.; Welty, L.A.; Banner, L.R.; Oppenheimer, S.B. Direct targeting of cancer cells: a multiparameter approach. Acta Histochem., 2005, 107(5), 335-344.
120. Huh, J.W.; Park, Y.A.; Lee, K.Y.; Sohn, S.K. Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. Yonsei Med. J., 2009, 50(5), 697-703.
121. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm., 2002, 235(1-2), 179-192.
122. Wang, C.; Ho, P.C.; Lim, L.Y. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int. J. Pharm., 2010, 400(1-2), 201-210.
123. Lu, Y.; Low, P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother., 2002, 51(3), 153-162.
124. Cummings, J.; McArdle, C.S. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br. J. Cancer, 1986, 53(6), 835-838.
125. Sudimack, J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev., 2000, 41(2), 147-162.
126. Kunii, R.; Onishi, H.; Machida, Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur. J. Pharm. Biopharm., 2007, 67(1), 9-17.
127. Kolhatkar, R.B.; Swaan, P.; Ghandehari, H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm. Res., 2008, 25(7), 1723-1729.
128. Ebrahimnejad, P.; Dinarvand, R.; Jafari, M.R.; Tabasi, S.A.; Atyabi, F. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Int. J. Pharm., 2011, 406(1-2), 122-127.
129. Kuo-Yung, C.; Yu-Der L. Ring-opening polymerization of - caprolactone initiated by the antitumor agent doxifluridine. Acta biomater., 2009, 5, 1075-1081.
130. Shuai, X.; Ai, H.; Nasongkla, N.; Kim, S.; Gao, J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Control. Release, 2004, 98, 415-426.
131. Xiong, M.P.; Yáñez, J.A.; Remsberg, C.M.; Ohgami, Y.; Kwon, G.S.; Davies, N.M.; Forrest, M.L. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J. Control. Release, 2008, 129, 33-40.
132. Liu, Q.; Li, R.T.; Qian, H.Q.; Yang, M.; Zhu, Z.S.; Wu, W.; Qian, X.P.; Yu, L.X.; Jiang, X.Q.; Liu, B.R. Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel- loaded poly(ethylene glycol)-poly(-caprolactone) nanoparticles. Int. J. Nanomedicine, 2012, 7, 281-295.
133. Ortiz, R.; Prados, J.; Melguizo, C.; Arias, J.L.; Ruiz, M.A.; Alvarez, P.J.; Caba, O.; Luque, R.; Segura, A.; Aránega, A. 5- Fluorouracil-loaded poly(-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. Int. J. Nanomedicine, 2012, 7, 95-107.
134. Luo, J.; Liu, X. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Protein Cell, 2012, 3(3), 182-197.
135. Steegmaier, M.; Hoffmann, M.; Baum, A.; Lénárt, P.; Petronczki, M.; Krssák, M.; Gürtler, U.; Garin-Chesa, P.; Lieb, S.; Quant, J.; Grauert, M.; Adolf, G.R.; Kraut, N.; Peters, J.M.; Rettig, W.J. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol., 2007, 17(4), 316-322.
136. Heidel, J.D.; Liu, J.Y.; Yen, Y.; Zhou, B.; Heale, B.S.; Rossi, J.J.; Bartlett, D.W.; Davis, M.E. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res., 2007, 13(7), 2207-2215.
137. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010, 464(7291), 1067-1070.
138. Hirakawa, Y.; Niki, H.; Oike, S.; Tagawa, S.; Hosokawa, S.; Yoshiyama, Y. Antibody recognizing antigen. US20100226974, September 9, 2010.
139. Hamaguchi, T.; Matsumura, Y.; Nakanishi, Y.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Niki, H.; Hosokawa, S.; Tagawa, T.; Kakizoe, T. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci., 2004, 95(7), 608-613.
140. Jain, K.K. Advances in the field of nanooncology. BMC Medicine, 2010, 8, 83-94.
141. Harasym, T.O.; Tardi, P.G.; Harasym, N.L.; Harvie, P.; Johnstone, S.A.; Mayer, L.D. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol. Res., 2007, 16(8), 361-374.
142. Batist, G.; Gelmon, K.A.; Chi, K.N.; Miller, W.H.; Chia, S.K.; Mayer, L.D.; Swenson, C.E.; Janoff, A.S.; Louie, A.C. Safety, pharmacokinetics, and efficacy of CPX-1 (Irinotecan HCl:Floxuridine) liposome injection in patients with advanced solid tumors. Clin. Cancer Res., 2009, 15(2), 692-700.
143. Lei, S.; Chien, P.Y.; Sheikh, S.; Zhang, A.; Ali, S.; Ahmad, I. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs, 2004, 15(8), 773-778.
144. Dash, A.K.; Trickler, W.J. Mucoadhesive nanoparticles for cancer treatment. U.S. Patent 20100323977, December 23, 2010.
145. Sternberg, L.R.; Byrd, J.C.; Hansson, G.C.; Liu, K.F.; Brealier, R.S. Alternative splicing of the human MUC2 gene. Arch. Biochem. Biophys., 2004, 421(1), 21-33.
146. Leuschner, C.; Kumar, C.S.S.R.; Hansel, W.; Hormes, J. In vivo imaging and therapy with magnetic nanoparticle conjugates. U.S. Patent 20090169478, July 2, 2009.
147. Levy, L.; Pottier, A.; Rouet, A.; Marill, L.; Devaux, C.; Germain, M. Inorganic nanoparticles of high density to destroy cells in-vivo. U.S. Patent 20110213192, September 1, 2011.
148. Zhao, H.; Shi, L. Nanoparticle compositions for nucleic acids delivery system. U.S. Patent 20110111044, May 12, 2011.